Technology evaluation: BAY-50-4798, Bayer.
Bayer is developing an IL-2-selective recombinant cytokine, BAY-50-4798, as a potential adjunct to standard chemotherapy in the treatment of various cancers, and for the potential treatment of HIV infection. BAY-50-4798 is currently undergoing phase II clinical trials.
Hartmann
Gunther
G
University of Munich, Division of Clinical Pharmacology, Ludwig-Maximilians Clinic, Ziemssenstrasse 1, 80336 München, Germany. gunther.hartmann@medinn.med.uni-muenchen.de
D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D010330:Patents as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; C082598:aldesleukin